Amprion and Modality.AI Break New Ground in Multimodal Assessment for Neurodegenerative Disease

SAN FRANCISCO–(BUSINESS WIRE)–Amprion, a global leader advancing diagnosis of neurodegenerative disorders through seed amplification testing, and Modality.AI, a leader in AI-enabled multimodal clinical assessments, today announced a collaboration to explore how molecular biomarkers and…


Click here to view the original article.